Aims/hypothesis. We have previously shown a strong relationship between high angiotensin-converting enzyme (ACE) activity, presence of the deletion (D) allele of the ACE gene and recall of severe hypoglycaemic events in patients with Type 1 diabetes. This study was carried out to assess this relationship prospectively. Methods. We followed 171 adult outpatients with Type 1 diabetes in a one-year observational study with the recording of severe hypoglycaemia. Participants were characterised by serum ACE activity and ACE genotype and not treated with ACE inhibitors or angiotensin II receptor antagonists.
tients with Type 1 diabetes spend as much as ten percent of the time at hypoglycaemic glucose levels [2] . To avoid progression of these frequent episodes into severe hypoglycaemia patients rely on maintenance of performance capacity [3] until hypoglycaemic symptoms are recognised and self-treated or until the next pre-scheduled meal is ingested.
Risk of severe hypoglycaemia is a major limiting factor for the achievement of good metabolic control [4] rendering prediction of individual risk of severe hypoglycaemia increasingly important. Loss of hypoglycaemic warning symptoms and blunted hormonal counterregulatory response are the most important known predictors of severe hypoglycaemia [4, 5] . However, even patients at high risk according to these pa-
Following the Diabetes Control and Complications
Trial [1] a growing demand for strict glycaemic control has emerged to avoid late diabetic complications in Type 1 diabetes. As a consequence the majority of patients with Type 1 diabetes experience mild hypoglycaemia on a regular basis and recent studies applying continuous glucose monitoring indicate that parameters have a highly varying inter-individual susceptibility to severe hypoglycaemia. This is reflected by the fact that experience of severe hypoglycaemia is highly skewed within cohorts of patients with Type 1 diabetes and that previous severe hypoglycaemia is a major, yet unexplained, risk factor for future episodes [6] , that suggests the influence of inherent, e.g. genetic, factors.
Hypoglycaemia and exercise share some common metabolic features. Thus, during endurance exercise, counterregulatory mechanisms similar to those of hypoglycaemia are activated to mobilise fuel. In healthy humans both antecedent exercise and antecedent hypoglycaemia attenuate symptoms and hormonal counterregulation during subsequent hypoglycaemia [7, 8] . In elite endurance athletes, who like patients with Type 1 diabetes spend considerable time with limited fuel availability, performance capacity has been associated with the angiotensin-converting enzyme (ACE) genotype as the insertion (I) allele of the ACE gene that confers low ACE activity, compared to the deletion (D) allele [9] , has been linked to superior performance capacity [10, 11, 12] .
This indicates a benefit of low ACE activity on performance when fuel supply is limited and prompted us to investigate the relation between ACE activity and risk of severe hypoglycaemia in Type 1 diabetes. In a hypothesis-generating retrospective survey, recall of severe hypoglycaemia was strongly related with both high serum ACE activity and DD genotype of the ACE gene [13] . The purpose of this study was to test the hypothesis that high ACE activity is a predictor of the risk of severe hypoglycaemia in patients with Type 1 diabetes.
Subjects and methods
Subjects and design. Consecutive adult (>18 years of age) outpatients with clinical Type 1 diabetes for more than 2 years were included in a 1-year prospective observational study that took place from October 1999 to March 2001 at Hillerød Hospital. Type 1 diabetes was defined by insulin treatment from the time of diagnosis and unstimulated C-peptide less than 300 pmol/l or stimulated (venous blood glucose concentration >12 mmol/l) C-peptide less than 600 pmol/l. Excluded from participation in the study were pregnant women, subjects on haemodialysis or suffering from concomitant malignant disease, and subjects treated with ACE inhibitors or angiotensin II receptor antagonists due to the interference of these drugs with the naturally occurring ACE activity. Of 260 patients invited to take part in the study, 209 (80%) gave informed consent to participate and of these, 171 subjects (82%) completed the study. During the study, 31 (15%) withdrew their consent, one died, and six subjects (3%) were excluded from the analysis due to initiation of ACE inhibitor treatment. The clinical characteristics of the participants (Table 1) did not differ from those of non-participants and dropouts (not shown). The study was approved by the regional Ethics Committee.
Base-line data. At base-line, an extended version of a questionnaire originally developed by another study [14] was completed by the participants to assess previous experience of hypoglycaemia and self-estimated state of hypoglycaemic awareness. State of awareness was classified according to the patients' ability to recognise symptoms, during a hypoglycaemic episode. Subjects always recognising their symptoms were categorised as having normal awareness, those usually recognising their symptoms as having impaired awareness, and those occasionally or never recognising their symptoms as having unawareness. There is at present no consensus on classification of awareness of hypoglycaemia and we chose this very simple method as it can be applied to almost all patients, it is easily translated and has been used by a number of groups [14, 15, 16] , either alone or as part of scoring systems. Furthermore, with regard to the clinical consequence of impaired awareness, i.e. risk of severe hypoglycaemia, it discriminates between groups of patients as good as other methods [13, 15, 16] . Data on a patients' history of diabetes were extracted from medical records [13] .
Laboratory analyses. At baseline, a blood sample was taken to characterise the participant. ACE genotype was assessed by polymerase chain reaction, including a check for misclassification of DD subjects using an insertion specific primer as [17] . Serum ACE activity was assessed by a kinetics-based assay (Sigma Diagnostics, St. Louis, Miss., USA). C-peptide was measured by radioimmunoassay (Autodelfia, Wallac Oy, Turku, Finland). Subjects were classified as being C-peptide negative if the value was below the detection limit of 10 pmol/l. HbA 1c was measured spectrophotometrically (DCA-2000, Bayer, Leverkusen, Germany; normal range 4.1%-6.4%; standardised against the Diabetes Control and Complications Trial) at each visit at the outpatient clinic and individual average values for the study period were calculated.
Reporting and classification of hypoglycaemia. Hypoglycaemia was reported monthly on questionnaires mailed to the participants. Events of severe hypoglycaemia, defined as episodes with symptoms of hypoglycaemia with need for assistance from another person, were reported by telephone within 24 h after the event. Structured telephone interviews were carried out blind to ACE status of the patients to establish the level of documentation, classify severity, and explore circumstances of the incidents. At the end of follow-up severe hypoglycaemia was reported retrospectively and in the case of missed reporting, telephone interviews were carried out.
Episodes of severe hypoglycaemia were validated according to Whipple's: (i) symptoms of hypoglycaemia; (ii) blood glucose below 3 mmol/l; and (iii) adequate response to glucose/glucagon treatment. Episodes fulfilling all criteria were classified as definite, those fulfilling two criteria with no alternative explanation of the symptoms were classified as probable and those with a concurring explanation fulfilling two criteria and those fulfilling only one criterion were classified as possible. Episodes recorded retrospectively were degraded by one class. Severity was sub-classified according to level of assistance and consciousness during the episode: (i) conscious during the event, but with need of assistance to treat orally; (ii) parenteral treatment necessary and/or coma or seizure during the event.
Mild hypoglycaemia was defined as episodes with symptoms familiar to the patient as hypoglycaemia and managed solely by the patient. These episodes were reported for the week preceding the return of the monthly questionnaires. Biochemical hypoglycaemia was defined as a blood glucose measurement below 3 mmol/l and was assessed by one monthly self-monitored 5-point blood glucose profile (before breakfast, lunch, and dinner, at bedtime, and at 3 a.m.). The proportion of hypoglycaemic values (below 3.0 mmol/l) was calculated for each subject.
Statistical analysis. Primary endpoint was the number of episodes of severe hypoglycaemia during the study period. Secondary parameters were the number of episodes of severe hypoglycaemia with coma or parenteral treatment, mean number of episodes of mild hypoglycaemia per week and the fraction of self-monitored blood glucose values below 3 mmol/l. Standard descriptive and non-parametric comparative statistics were used to characterise and compare groups. The number of severe hypoglycaemic episodes and the number of severe hypoglycaemic episodes with coma were analysed by a frailty model for recurrent events (an extension of the log-linear Poisson model including a gamma-distributed variation between patients) that takes into account the highly skewed distribution of events of severe hypoglycaemia [18] . The effect of an explanatory factor is reported as relative risk with 95% confidence limits. A log-linear model was applied for the effect of serum ACE activity and for this continuous variable the relative risk is reported in a clinically relevant assay-independent manner. As median risk of subjects in the fourth quartile relative to that of subjects in the first quartile, corresponding to the risk of a subject with serum ACE activity of 64 U/l relative to risk of a person with serum ACE of 30 U/l. The relative importance of serum ACE activity and established risk factors of severe hypoglycaemia were evaluated by backward stepwise multiple regression analyses. History of previous severe hypoglycaemia was not included in these analyses as this factor is not an independent factor but rather a composite product of other risk factors including state of awareness, diabetes duration, C-peptide status and ACE activity [13] . Other correlations were analysed by standard linear regression.
Data were processed by use of the SPSS software package (Version 10.0) and a non-commercial software program. A two-tailed p value of less than 0.05 was considered statistically significant.
Results
During the study 193 episodes of severe hypoglycaemia (1.1 episode per patient-year) were reported during the study. These episodes were accounted for by 66 (39%) patients. Coma or need for parental treatment were reported in 29% of the episodes (0.3 episodes per patient-year). Of the severe hypoglycaemic events 46% were classified as definite, 51% as probable, and 3% as possible. The overall mean rate of mild hypoglycaemia was 1.7 episodes per patient-week. The mean fraction of blood glucose readings below 3 mmol/l was 3.7%.
The distribution of the ACE genotypes (Table 1 ) was equal to the distribution in a large Danish population sample and was in Hardy-Weinberg equilibrium (p=0.7). The mean (SD) serum ACE activity was 48 (17) U/l. Serum ACE activity was related with ACE genotype (p<0.0001) but no other differences in clinical characteristics between the genotypes were observed (Table 1 ). There was a weak positive relationship between serum ACE activity and age (R 2 : 0.025; p=0.04) but not between ACE activity and duration of diabetes (p=0.86). Likewise, there was a weak positive relationship between serum ACE activity and awareness of hypoglycaemia (R 2 ACE and severe hypoglycaemia. There was a positive relationship between serum ACE activity and the rate of severe hypoglycaemia (relative rate of subjects in fourth quartile compared to subjects in first quartile: 2.7; p=0.0007) (Fig. 1, Table 2 ). A similar relationship was observed for the subset of events with coma (Table 3). The proportion of patients reporting severe hypoglycaemia increased with increasing serum ACE severe hypoglycaemia in the subset of C-peptide negative subjects (relative rate of subjects in fourth quartile compared to subjects in first quartile: 4.2; p=0.003), but this did not reach statistical significance in the C-peptide positive subgroup (relative rate of subjects in fourth quartile compared to subjects in first quartile: 1.9; p=0.08) (Fig. 2a) .
There was a non-significant overall tendency towards a higher rate of severe hypoglycaemia in subjects carrying the D-allele ( Other risk-factors and severe hypoglycaemia. At univariate analysis, impaired awareness of hypoglycaemia, undetectable C-peptide, and increasing duration of diabetes were associated with an increased rate of severe hypoglycaemia (Table 2 ). In contrast, there was no relation between HbA 1c or age and rate of severe hypoglycaemia.
Multivariate analyses of severe hypoglycaemia. The relative importance of serum ACE activity and established risk factors of severe hypoglycaemia was evaluated in a multiple regression analysis including serum ACE, state of awareness of hypoglycaemia, Cpeptide status, HbA 1c , age and duration of diabetes (Table 4) . After exclusion of non-significant parameters, only high serum ACE activity and impaired awareness or unawareness remained important. The association between serum ACE activity and the rate of severe hypoglycaemia in both subjects with normal and impaired awareness and unawareness (relative rate of subjects in fourth quartile compared to subjects in first quartile: 4.3, 1.9 and 6.5; p=0.047, p=0.025 and p=0.040, respectively) (Fig. 2b) . There was no differential effect of ACE activity in the three groups (p=0.28).
As the patients' own estimate of awareness of hypoglycaemia is influenced by previously experienced severe hypoglycaemia, a similar regression analysis Table 5 ). The only risk factors remaining significant in this approach were high serum ACE activity and long duration of diabetes. The relationship between serum ACE activity and rate of severe hypoglycaemia remained significant in the subgroup with diabetes for 20 years or more (relative rate of subjects in fourth quartile compared to subjects in first quartile: 3.2, p=0.003) but not in subgroups with a shorter duration (Fig. 2c ).
Mild and biochemical hypoglycaemia. There was no relation between serum ACE activity and the self-reported rate of mild hypoglycaemia or proportion of self-monitored blood glucose values below 3 mmol/l (p=0.59 and p=0.60, respectively). The rate of mild hypoglycaemia was not related to the rate of severe hypoglycaemia (p=0.28) but the proportion of low self-monitored blood glucose values tended to be positively related with rate of severe hypoglycaemia (relative rate per 1% increment: 1.067; p=0.062).
Discussion
This study identifies high naturally occurring ACE activity as a novel genetically influenced predictor of severe hypoglycaemia in unselected subjects with Type 1 diabetes. This is based on the distribution of thoroughly validated prospectively recorded events of severe hypoglycaemia according to a definition comparable to that used in the Diabetes Control and Complications Trial [1] as well as according to a more restrictive definition by the presence of coma or need for parenteral treatment. The relative rate of 2.7 among subjects with serum ACE activity in the highest quartile compared to those in the lowest quartile is in accordance with the result of our preliminary retrospective survey [13] as well as with recent preliminary data from a Swedish study in children with Type 1 diabetes [19] . The significance of the relationship between high ACE activity and the rate of severe hypoglycaemia is further stressed by our multiple regression analysis, in which serum ACE activity outweighed other objectively measured risk factors such as C-peptide status, duration of diabetes, age, and HbA 1c . The fact that the impact of ACE activity was most significant in subjects with loss of residual beta-cell function and long duration of diabetes indicates that the influence of ACE activity is most pronounced in subjects with reduced counterregulatory capacity [2, 3] . There was a relationship between high ACE activity and impaired awareness of hypoglycaemia, indicating that some of the effect could be due to an interaction between ACE activity and awareness, but the multiple regression analysis showed that the major effect of ACE activity was independent on state of awareness in accordance with the lack of physiological connection between ACE and awareness. The intra-individual serum ACE activity is stable [20] and is predominantly determined by the I/D polymorphism of the ACE gene [9] . In accordance with the relationship between high serum ACE activity and risk of severe hypoglycaemia, the D allele was associated with an increased risk of severe hypoglycaemia in C-peptide negative subjects. In our retrospective survey an effect was shown among all patients [13] . The concordance between the results for the genotype and for serum ACE activity adds substantially to the validity of the result and could indicate a causative relationship between high ACE activity and increased risk of severe hypoglycaemia.
Serum ACE activity can be evaluated by a simple blood test, widely available as a routine test. Due to the intra-individual stability of enzyme activity [20] , measurement of serum ACE activity could be a supplement to evaluation of other risk factors in the assessment of future risk of severe hypoglycaemia. Determination of serum ACE or ACE genotype might identify patients, who should be regularly evaluated with regard to residual beta-cell function and awareness of hypoglycaemia in order to prevent high rates of severe hypoglycaemia. The fact that high natural ACE activity is associated with susceptibility to severe hypoglycaemia, while in some studies it has been linked to the development of nephropathy [21] and macrovascular complications [22] indicates a narrow therapeutic window with regard to glycaemic control in subjects with high natural ACE activity.
The association between high ACE activity and the high risk of severe hypoglycaemia raises the possibility of pharmacological prevention of severe hypoglycaemia by means of ACE inhibitors. In contrast with our findings, an association between treatment for severe hypoglycaemia and use of ACE inhibitors has been indicated in a few registry based studies [23, 24] . These studies are, however, hampered by important clinical differences between cases and control group (e.g. duration of diabetes) that could account for the finding, which in accordance was not found in a controlled trial [25] or in our previous survey [13] . ACE inhibitor treatment has been shown to improve insulin sensitivity in subjects with various components of the metabolic syndrome [26] , an effect with potential risk of hypoglycaemia, but no such effect seems to have been reported in normal subjects or in patients with Type 1 diabetes. Thus, the preventive potential of ACE inhibitors and angiotensin II receptor antagonists should be evaluated in Type 1 diabetic subjects at high risk of severe hypoglycaemia.
Based on the association between the I allele of the ACE gene and superior performance capacity in elite endurance athletes [10, 11, 12] , the relation between serum ACE activity and risk of severe hypoglycaemia could be explained by superior cognitive or overall performance of subjects with low ACE activity during hypoglycaemia. This is supported by the fact that measures of mild and biochemical hypoglycaemia were not affected by serum ACE activity, indicating that subjects, independent of their ACE activity, experience hypoglycaemia with equal frequency but that those with low ACE activity to a greater extent are able to compensate the condition by self-treatment or maintenance of near-normal function until the next pre-scheduled meal. Hypothetically, ACE could act directly on the target organs similarly to what is observed during hypoxia [27] or indirectly via the counterregulatory response [28] . In similarity with the effect of training in muscle of non-diabetic human subjects with the II genotype [29] , repetitive exposure to hypoglycaemia in subjects with low ACE activity might increase metabolic efficiency, which could be beneficial for maintenance of function during subsequent episodes of hypoglycaemia. Furthermore, low ACE activity could mediate resistance against -or reduced production of -toxic substances, e.g. reactive oxygen species in fuel deficient tissues caused by either decreased angiotensin II production or bradykinin degradation. This is supported by the activation of the renin-angiotensin system during experimental hypoglycaemia in humans [30] and the finding of high levels of angiotensin II to induce intracellular oxidative stress [31] and that bradykinin seems responsible for the beneficial effect on cardiac nitric oxide induced by ACE inhibitors [32] . Alternatively, a low ACE activity could enhance substrate mobilisation by interference with hormonal counterregulation, e.g. the response of [28, 33] or sensitivity to [34, 35] catecholamines that constitute the primary hormonal defence against hypoglycaemia in Type 1 diabetes when the glucagon response is lost.
The overall rate of severe hypoglycaemia of 1.1 episode per patient-year in this study was comparable to the result of other studies of unselected cohorts from western Europe [14, 36, 37] . These figures are all higher than those of some other studies [38] , including the Diabetes Control and Complications Trial [1] . The discrepancy is probably explained by differences in definition and recording of severe hypoglycaemia and in a different selection of patients rather than by a real difference in incidence among comparable subjects.
Conclusively, in terms of hypoglycaemia, our study introduces evaluation of genetic factors to explain the highly varying individual susceptibility to severe hypoglycaemia and future studies might show if other functional genetic polymorphisms influence the risk of severe hypoglycaemia. In a broader perspective, our study adds to the impression of an impact of ACE activity on basic human metabolism in situations with limited substrate availability and could thereby contribute to the emerging understanding of mechanisms underlying the beneficial metabolic effects of ACE inhibition [39] .
